LunX-CAR T Cells as a Targeted Therapy for Non-Small Cell Lung Cancer

[1]  H. Einsele,et al.  ROR1-CAR T-cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models. , 2019, JCI insight.

[2]  Jeremy L. Davis,et al.  Cancer targeting by TCR gene-engineered T cells directed against Kita-Kyushu Lung Cancer Antigen-1 , 2019, Journal of Immunotherapy for Cancer.

[3]  Matthew N. Metzinger,et al.  Chimeric Antigen Receptor T-Cell Therapy: Reach to Solid Tumor Experience , 2019, Oncology.

[4]  D. Carbone,et al.  DLL3: an emerging target in small cell lung cancer , 2019, Journal of Hematology & Oncology.

[5]  Shiyou Li,et al.  Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy , 2019, Frontiers of Medicine.

[6]  Suna Wang,et al.  Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer , 2019, Journal of Hematology & Oncology.

[7]  A. Yoshimura,et al.  Nr4a transcription factors limit CAR T cell function in solid tumors , 2019, Nature.

[8]  M. Tsao,et al.  Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15 , 2019, Journal of Immunotherapy for Cancer.

[9]  Liming Lu,et al.  Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo , 2018, Experimental and therapeutic medicine.

[10]  Wei Yang,et al.  FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells , 2018, Nature.

[11]  Hongzhou Lu,et al.  Bi-specific ligand-controlled chimeric antigen receptor T-cell therapy for non-small cell lung cancer. , 2018, Bioscience trends.

[12]  F. Passiglia,et al.  Vaccine and immune cell therapy in non-small cell lung cancer. , 2018, Journal of thoracic disease.

[13]  P. Adusumilli,et al.  Driving CARs on the uneven road of antigen heterogeneity in solid tumors. , 2018, Current opinion in immunology.

[14]  He Li,et al.  Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice , 2018, Cell Death & Disease.

[15]  M. Ellis,et al.  TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer. , 2018, Cancer research.

[16]  Wei Wu,et al.  Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer , 2017, Cancers.

[17]  Ning Li,et al.  Chimeric Antigen Receptor-Modified T Cells Redirected to EphA2 for the Immunotherapy of Non-Small Cell Lung Cancer , 2017, Translational oncology.

[18]  P. Adusumilli,et al.  CAR T-cell therapy for lung cancer and malignant pleural mesothelioma. , 2017, Translational research : the journal of laboratory and clinical medicine.

[19]  Hao Liu,et al.  CD28 and 41BB Costimulation Enhances the Effector Function of CD19-Specific Engager T Cells , 2017, Cancer Immunology Research.

[20]  M. Redinbo,et al.  Identification of BPIFA1/SPLUNC1 as an epithelium-derived smooth muscle relaxing factor , 2017, Nature Communications.

[21]  Yangqiu Li,et al.  PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells , 2017, Oncoimmunology.

[22]  Yao Wang,et al.  Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma , 2017, Journal of Hematology & Oncology.

[23]  W. Han,et al.  Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer , 2016, Science China Life Sciences.

[24]  Brian Keith,et al.  Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. , 2016, Immunity.

[25]  Michel Sadelain,et al.  Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors. , 2016, Cancer discovery.

[26]  Xiaohu Zheng,et al.  Lung specific X protein as a novel therapeutic target for lung cancer , 2015, Oncoimmunology.

[27]  Xiaohu Zheng,et al.  Targeting LUNX inhibits non-small cell lung cancer growth and metastasis. , 2015, Cancer research.

[28]  M. Sadelain,et al.  Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity , 2014, Science Translational Medicine.

[29]  D. Torigian,et al.  Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies , 2013, Cancer Immunology Research.

[30]  M. Caligiuri,et al.  CS1-Specific Chimeric Antigen Receptor (CAR)-Engineered Natural Killer Cells Enhance In Vitro and In Vivo Anti-tumor Activity Against Human Multiple Myeloma , 2013, Leukemia.

[31]  K. Rabe,et al.  Management of non-small-cell lung cancer: recent developments , 2013, The Lancet.

[32]  B. Stripp,et al.  Antimicrobial Activity of PLUNC Protects against Pseudomonas aeruginosa Infection , 2011, The Journal of Immunology.

[33]  J. Olsen,et al.  SPLUNC1 regulates airway surface liquid volume by protecting ENaC from proteolytic cleavage , 2009, Proceedings of the National Academy of Sciences.

[34]  L. Bingle,et al.  Phylogenetic and evolutionary analysis of the PLUNC gene family , 2004, Protein science : a publication of the Protein Society.

[35]  G. Ronnett,et al.  Plunc, a Member of the Secretory Gland Protein Family, Is Up-regulated in Nasal Respiratory Epithelium after Olfactory Bulbectomy* , 2002, The Journal of Biological Chemistry.

[36]  A. Tanigami,et al.  Isolation of a novel human lung‐specific gene, LUNX, a potential molecular marker for detection of micrometastasis in non‐small‐cell lung cancer , 2001, International journal of cancer.